Polpharma to increase market segments, and expand research and development

Starogard Gdanski-based pharmaceutical company Polpharma is planning to spend zl. 600 million over the next five years on development, entering new market segments and increasing its market share from 5.7% to 10%. The management Polpharma, the largest national drug producer, stated that they would substantially increase spending on R&D and find money for enlarging plants. "We do not know the precise value of the investment," said company president Pawel Mirovsky. He added that Polpharma is hoping to achieve its goal by starting production on a new generation of medicines. The company will enter new segments for asthma and diabetes treatment. At present the company has focused on producing pharmaceuticals for cardiology, gastrology and neurological treatments. Two years ago, investors in Polpharma acquired 80% share capital of the company for zl. 350 million. They have been obliged to further capitalize Polpharma with zl. 100 million. Since it has opened, the company has constructed a plant in Starogard Gdanski worth zl. 200 million. (Puls Biznesu, p. 12) M.M.